Home Sectors Healthcare Present Technicals: Illumina (NASDAQ: ILMN)

Present Technicals: Illumina (NASDAQ: ILMN)


Illumina is in the healthcare sector and trades as part of the medical diagnostics and research industry. The company CEO is Francis A. DeSouza. Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

Previous Intraday Trading Performance:

The ILMN stock showed a previous change of 1.13% with an open at 311.64 and a close of 312.45. It reached an intraday high of 315.50 and a low of 311.64.

SeekingAlpha:  May And June Outlook On Illumina Inc.


The stock has a market cap of $45.9b with 147.0m shares outstanding, of which the float is 143.9m shares. Trading volume reached 599,671 shares compared to its average volume of 1,021,834 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Illumina shares returned 3.95% and in the past 30 trading days it returned -7.66%. Over three months, it changed 2.53%. In one year it has changed 15.37% and within that year its 52-week high was 372.61 and its 52-week low was 261.61. ILMN stock is 19.43% above its 52 Week Low.

Our calculations show a 200 day moving average of 317.89 and a 50 day moving average of 315.07. Currently ILMN stock is trading -1.71% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

SeekingAlpha:  May And June Outlook On Illumina Inc.


The last annual fiscal EPS for the company was reported at 5.56 that ended on 31st of December 2018, which according to the previous close, that is a PE of 56.20. Based on 9 analyst estimates, the consensus EPS for the next quarter is 1.34. The TTM EPS is 5.72, which comes to a TTM PE of 54.62. Historically, the PE high was 224.30 and the PE low was 38.40. If the stock reached its PE low, that would represent a price of 219.66, which is a decrease of -29.70%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 1.57
4thQtr of 2018 1.41
3rdQtr of 2018 1.33
2ndQtr of 2018 1.41
1stQtr of 2018 1.41

Base on our calculations, the intrinsic value per share is 160.00, which means it may be overvalued by -95.28%.

Indicators to Watch:

The current calculated beta is 1.08.

Business Wire:  Alternative Data Provides Significant and Sustainable Investing Edge, Reveals Greenwich Associates Research

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 24.34%, return on assets is 13.16%, profit margin is 23.82%, price-to-sales is 13.37 and price-to-book is 11.53.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 4  :Past Performance Score
 4  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.